Aclarion partners with PRIA Healthcare for Nociscan reimbursement strategy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St set to open higher as chip stocks extend recovery; earnings in focus
- Oil prices rise over 2% on fresh attacks by US and Iran
- Chip stocks extend global rebound following last week's rout
- Citi's Chew says U.S. stock positioning unwind may not be over
- Adobe, Salesforce and Intuit fall as Morgan Stanley begins cautious coverage
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform
June 9, 2026 7:00 AM EDTPartnership supports reimbursement strategy and U.S. commercial expansion for Aclarions AI-driven platform for chronic low back pain.
Program aims to follow successful reimbursement wins in the UK that are translating into sustained scan volume growth in step with reduced market access barriers
BROOMFIELD, Colo., June 09, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (Aclarion or the Company) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company... More
